Invivyd (NASDAQ:IVVD) Shares Down 3.8% – Here’s Why

Invivyd, Inc. (NASDAQ:IVVD) shares were down 3.8% on Tuesday . The stock traded as low as $2.42 and last traded at $2.4050. Approximately 206,829 shares traded hands during trading, a decline of 97% from the average daily volume of 7,828,522 shares. The stock had previously closed at $2.50.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on the stock. HC Wainwright boosted their price target on shares of Invivyd from $5.00 to $10.00 and gave the stock a “buy” rating in a research note on Friday, October 31st. D. Boral Capital reaffirmed a “hold” rating on shares of Invivyd in a research note on Tuesday, November 25th. Cantor Fitzgerald began coverage on Invivyd in a research report on Monday, October 6th. They set an “overweight” rating and a $10.00 target price on the stock. Zacks Research upgraded shares of Invivyd from a “strong sell” rating to a “hold” rating in a report on Thursday, November 13th. Finally, D Boral Capital lowered Invivyd from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, November 25th. Two analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Hold” and an average price target of $7.33.

Invivyd Price Performance

The stock has a fifty day moving average price of $1.82 and a two-hundred day moving average price of $1.19. The company has a market cap of $502.38 million, a P/E ratio of -4.61 and a beta of 0.61.

Invivyd (NASDAQ:IVVD) last announced its quarterly earnings data on Thursday, November 6th. The company reported ($0.06) earnings per share for the quarter, missing the consensus estimate of ($0.05) by ($0.01). Invivyd had a negative net margin of 119.63% and a negative return on equity of 92.97%. The firm had revenue of $13.13 million during the quarter, compared to analyst estimates of $12.00 million. As a group, analysts forecast that Invivyd, Inc. will post -1.64 earnings per share for the current year.

Insider Activity at Invivyd

In other news, Director Kevin F. Mclaughlin acquired 50,000 shares of the business’s stock in a transaction that occurred on Wednesday, November 19th. The stock was acquired at an average cost of $2.50 per share, for a total transaction of $125,000.00. Following the completion of the acquisition, the director owned 50,000 shares in the company, valued at approximately $125,000. The trade was a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 25.40% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Invivyd

Large investors have recently added to or reduced their stakes in the stock. Catalyst Funds Management Pty Ltd acquired a new position in shares of Invivyd during the 2nd quarter worth about $27,000. Vanguard Personalized Indexing Management LLC raised its holdings in Invivyd by 238.6% in the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 39,941 shares of the company’s stock valued at $29,000 after acquiring an additional 28,146 shares in the last quarter. Bank of America Corp DE boosted its stake in Invivyd by 330.5% during the third quarter. Bank of America Corp DE now owns 49,252 shares of the company’s stock worth $54,000 after buying an additional 37,811 shares in the last quarter. Jefferies Financial Group Inc. bought a new stake in Invivyd in the 3rd quarter valued at $102,000. Finally, Bridgeway Capital Management LLC acquired a new position in shares of Invivyd in the 3rd quarter worth approximately $109,000. Institutional investors own 70.36% of the company’s stock.

Invivyd Company Profile

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.